Docoh
Loading...

BCLI Brainstorm Cell Therapeutics

Filed: 17 Nov 20, 8:00am

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 17, 2020

 

Brainstorm Cell Therapeutics Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 001-36641 20-7273918
(State or other jurisdiction of
incorporation)
 (Commission File No.) (IRS Employer Identification No.)

 

1325 Avenue of Americas, 28th Floor 
New York, NY10019
(Address of principal executive offices)(Zip Code)

 

(201) 488-0460

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.00005 par valueBCLI

NASDAQ Stock Market LLC

(Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

  

 

 

 

Item 8.01.Other Events.

 

On November 17, 2020, Brainstorm Cell Therapeutics Inc. (the “Company”) issued a press release announcing Topline Results from its NurOwn® Phase 3 ALS Study. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. 

 

The Company will host a conference call and live webcast at 8:30 am ET on Tuesday, November 17, 2020 to discuss the Topline Results from its NurOwn® Phase 3 ALS Study. A live webcast of the conference call may be accessed by visiting the Investors & Media section of the Company’s website at http://www.ir.brainstorm-cell.com.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No. Description
99.1 Press Release issued by Brainstorm Cell Therapeutics Inc., dated November 17, 2020
104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 BRAINSTORM CELL THERAPEUTICS INC.
   
Date: November 17, 2020By:/s/ Chaim Lebovits
  Chaim Lebovits
 Chief Executive Officer